Galapagos/$GLPG
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Ticker
$GLPG
Sector
Primary listing
Employees
704
Headquarters
Website
Galapagos Metrics
BasicAdvanced
$2B
-
-$7.76
-0.05
-
Price and volume
Market cap
$2B
Beta
-0.05
52-week high
$37.78
52-week low
$22.59
Average daily volume
124K
Financial strength
Current ratio
8.626
Quick ratio
8.533
Long term debt to equity
0.236
Total debt to equity
0.307
Interest coverage (TTM)
-149.99%
Profitability
EBITDA (TTM)
-325.219
Gross margin (TTM)
-72.21%
Net profit margin (TTM)
-151.94%
Operating margin (TTM)
-111.14%
Effective tax rate (TTM)
4.18%
Revenue per employee (TTM)
$480,900
Management effectiveness
Return on assets (TTM)
-5.19%
Return on equity (TTM)
-16.72%
Valuation
Price to revenue (TTM)
6.084
Price to book
0.71
Price to tangible book (TTM)
0.71
Price to free cash flow (TTM)
-6.076
Free cash flow yield (TTM)
-16.46%
Free cash flow per share (TTM)
-5.115
Growth
Revenue change (TTM)
10.31%
Earnings per share change (TTM)
-311.04%
3-year revenue growth (CAGR)
-20.78%
10-year revenue growth (CAGR)
14.43%
3-year earnings per share growth (CAGR)
327.42%
10-year earnings per share growth (CAGR)
11.88%
Galapagos News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of $2B as of December 17, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of December 17, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of December 17, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) has a beta rating of -0.05. This means that it has an inverse relation to market volatility.